Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification - Fig 2

(A) Kaplan-Meier curves for biochemical progression-free survival of all patients stratified according to pretreatment blood prostate-specific antigen (PSA) levels: ≤ 10 ng/ml vs. > 10 ng.ml. (B) Kaplan-Meier curves for biochemical progression-free survival of patients with Gleason score (GS) ≤ 6 stratified according to pretreatment blood PSA levels: ≤ 10 ng/ml vs. > 10 ng.ml.